Retatrutide Weight Loss Breakthrough: Triple-Hormone Drug Matches Surgery Results

retatrutide weight loss triple agonist obesity drug editorial cover

Eli Lilly’s retatrutide weight loss trial achieved up to 30.3% body weight reduction, matching bariatric surgery. Phase 3 TRIUMPH-1 data, mechanism, and access analysis.